for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mirum Pharmaceuticals Inc

MIRM.OQ

Latest Trade

18.74USD

Change

0.78(+4.34%)

Volume

51,135

Today's Range

17.84

 - 

18.78

52 Week Range

12.84

 - 

22.10

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
17.96
Open
18.00
Volume
51,135
3M AVG Volume
2.96
Today's High
18.78
Today's Low
17.84
52 Week High
22.10
52 Week Low
12.84
Shares Out (MIL)
30.64
Market Cap (MIL)
574.16
Forward P/E
-4.09
Dividend (Yield %)
--

Next Event

Q4 2021 Mirum Pharmaceuticals Inc Earnings Release

Latest Developments

More

Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher

Mirum Pharmaceuticals Reports Q3 Loss Per Share $1.55

Takeda Pharmaceutical Co Ltd Partners With Takeda To Develop Maralixibat For Rare Pediatric Liver Diseases In Japan

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its focuses on diseases for which the unmet medical need is high and the biology for treatment is clear. Its pipeline consists of two clinical-stage product candidates with mechanisms of action that have potential utility across a range of orphan liver diseases. The Company initially developing maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis (PFIC), and Alagille syndrome (ALGS). It has commenced enrollment in the Phase III clinical trial in PFIC and planning to initiate a Phase III clinical trial in ALGS. The Company is developing volixibat for the treatment of adult patients with cholestatic liver diseases including primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy (ICP) and primary biliary cholangitis (PBC).

Industry

Biotechnology & Drugs

Contact Info

950 Tower Ln Ste 1050

FOSTER CITY, CA

94404-4251

United States

+1.650.6674085

https://mirumpharma.com/

Executive Leadership

Michael G. Grey

Chairman of the Board

Christopher Peetz

President, Chief Executive Officer, Co-Founder, Director

Ian Clements

Chief Financial Officer

Peter Radovich

Chief Operating Officer

Pamela Vig

Chief Scientific Officer

Key Stats

1.57 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020

0.0K

2021(E)

0.1K
EPS (USD)

2019

-4.580

2020

-4.090

2021(E)

-4.516
Price To Earnings (TTM)
--
Price To Sales (TTM)
35.88
Price To Book (MRQ)
10.10
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-116.12
Return on Equity (TTM)
-94.81

Latest News

Latest News

Mirum's oral drug becomes first U.S. approved Alagille syndrome therapy

Mirum Pharmaceuticals Inc said on Wednesday its drug became the first U.S. approved therapy for treating itching in patients with a rare liver disorder called Alagille syndrome (ALGS).

FDA approves Mirum Pharma's drug for itching associated with rare liver disorder

Mirum Pharmaceuticals Inc said on Wednesday that the U.S. Food and Drug Administration has approved its drug to treat itching in patients with Alagille syndrome, making it the first approved therapy for treating symptoms of the genetic disorder. (Reporting by Mrinalika Roy...

BRIEF-Mirum’S Maralixibat Shows Transplant-Free Survival For Pediatric Patients With Progressive Familial Intrahepatic Cholestasis

* MIRUM’S MARALIXIBAT DEMONSTRATES TRANSPLANT-FREE SURVIVAL FOR PEDIATRIC PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS

BRIEF-Mirum Pharmaceuticals Reports First Quarter 2020 Financial Results

* MIRUM PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

BRIEF-Mirum Pharmaceuticals Reports Fourth Quarter And Full Year 2019 Financial Results And Provides Corporate Update

* MIRUM PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

IFR US ECM Calendar

Mirum Pharmaceuticals (US, biotech) – $48m FO. 2.4m shares (100% prim) at $20.00 versus $20.99 last sale and $23.03 launch. CITI, EVER, GUGG.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up